Internal Medicine, Infectious Disease · Baltimore, MD
NPI
1114902210
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
827 Linden Ave, Suite 3e-F
Baltimore, MD, 21201
Phone (410) 225-8404
Groups this clinician bills Medicare through
Medicare paid, 2024
$5,437
51 services
Medicare patients, 2024
38
Average age 70
Drug cost, 2024
$4.0M
1,660 prescriptions
Company payments, 2025
$392
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chandralekha Banerjee was code 99233 (hospital e&m - subsequent), 23 times for 19 patients. In total Chandralekha Banerjee billed 51 services in 4 codes, and Medicare paid $5,437.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-11-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 23 | 19 | $96.48 | $2,219 |
| 99223 Hospital E&M - Initial | Facility | 13 | 13 | $140.87 | $1,831 |
By year: 2022 $122K for 1,424 services; 2023 $65K for 790 services; 2024 $5,437 for 51 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chandralekha Banerjee prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 472 prescriptions and refills. In total Chandralekha Banerjee wrote 1,660 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 472 | 472 | 48 | $1.8M |
| Dovato Dolutegravir Sodium/Lamivudine | 189 | 189 | 19 | $555K |
| Tivicay Dolutegravir Sodium | 185 | 185 | 19 | $596K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 84 | 88 | 12 | $312K |
| Descovy Emtricitabine/Tenofov Alafenam | 61 | 65 | Under 11 | $126K |
| Edurant Rilpivirine Hcl | 60 | 64 | Under 11 | $89K |
| Abacavir Abacavir Sulfate | 50 | 52 | Under 11 | $17K |
| Atorvastatin Calcium Generic | 46 | 90 | 12 | $181 |
| Juluca Dolutegravir/Rilpivirine | 32 | 32 | Under 11 | $111K |
| Lamivudine Generic | 29 | 31 | Under 11 | $3,109 |
| Valacyclovir Valacyclovir Hcl | 27 | 37 | Under 11 | $754 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 25 | 25 | Under 11 | $114K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 24 | 24 | Under 11 | $86K |
| Maraviroc Generic | 20 | 20 | Under 11 | $22K |
| Pifeltro Doravirine | 20 | 20 | Under 11 | $33K |
Brand drugs: 1,208 claims; generic drugs: 452 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chandralekha Banerjee $392 ($392 in general payments such as food, travel and fees) from 3 companies. The largest payer was Gilead Sciences, Inc. with $338.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.